Post neoadjuvant therapy in Triple Negative Breast Cancer

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about triple negative Breast Cancer. Where is the role of immunotherapy in early triple negative breast cancer? What is the benefit it can provide in the neoadjuvant and post-neoadjuvant setting on the basis of the current scientific evidence?

Treatment options for early, HR+, HER2- Breast Cancer

Professor Hope Rugo were speaker and co-author of several presentations at this years San Antonio Breast Cancer Symposium. We asked her about early stage HR+, HER2-negative breast cancer. For example, updated results of TAILORx trial on the need for adjuvant chemo and the 42 months data of the MonrachE trial.

Highlights of the San Antonio Breast Cancer Symposium 2022

Professor Virginia Kaklamani speak about the novelties and state of the art treatment presented at SABCS 2022. (DESTINY-Breast02 trial Trastuzumab Deruxtecan,  CDK4/6i elacestrant, EMERALD trial, AKT inhibitor capivasertib,POSITIVE trial)